Equillium, Inc. (EQ) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1248710,
    "name": "Equillium, Inc.",
    "stock_name": "Equillium, Inc.",
    "full_name": "Equillium, Inc.",
    "name_url": "stocks-analysis/equillium-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "0.87",
    "chg": 0.01,
    "chgp": "1.54%",
    "dir": 1,
    "prev_price": "0.86",
    "mcapval": "111.87",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US29446K1060",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "519.87 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/equillium-inc-1248710-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Equillium, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-equillium-inc-technically-bullish-or-bearish-3548073",
        "imagepath": "",
        "date": "2025-09-20 20:09:08",
        "description": "As of 5 September 2025, the technical trend for Equillium, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by a bullish MACD on the weekly timeframe and bullish moving averages on the daily timeframe. However, the weekly RSI indicates bearish momentum, suggesting some caution. The stock has shown a strong year-to-date return of 100.48%, significantly outperforming the S&P 500's 12.22% over the same period. Overall, while the bullish indicators are strong, the mixed signals from the RSI warrant attention...."
      },
      {
        "title": "Is Equillium, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-equillium-inc-overvalued-or-undervalued-3544238",
        "imagepath": "",
        "date": "2025-09-20 18:41:17",
        "description": "As of 23 March 2023, the valuation grade for Equillium, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.28, an EV to EBIT of 0.05, and an EV to EBITDA of 0.06, which suggest that the market may be pricing in more value than the underlying fundamentals support. \n\nWhen compared to peers, Equillium's EV to EBITDA ratio of -4.9420 is significantly worse than OncoCyte Corp.'s -2.1276, highlighting a concerning valuation relative to its industry. Additionally, the company's recent stock performance shows a stark contrast to the S&P 500, with a 1-week return of -24.62% compared to the index's 1.05%, further reinforcing the notion that Equillium is currently overvalued...."
      }
    ],
    "total": 7,
    "sid": "1248710",
    "stock_news_url": "https://www.marketsmojo.com/news/equillium-inc-1248710"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Equillium, Inc. technically bullish or bearish?

2025-09-20 20:09:08

As of 5 September 2025, the technical trend for Equillium, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by a bullish MACD on the weekly timeframe and bullish moving averages on the daily timeframe. However, the weekly RSI indicates bearish momentum, suggesting some caution. The stock has shown a strong year-to-date return of 100.48%, significantly outperforming the S&P 500's 12.22% over the same period. Overall, while the bullish indicators are strong, the mixed signals from the RSI warrant attention....

Is Equillium, Inc. overvalued or undervalued?

2025-09-20 18:41:17

As of 23 March 2023, the valuation grade for Equillium, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.28, an EV to EBIT of 0.05, and an EV to EBITDA of 0.06, which suggest that the market may be pricing in more value than the underlying fundamentals support. When compared to peers, Equillium's EV to EBITDA ratio of -4.9420 is significantly worse than OncoCyte Corp.'s -2.1276, highlighting a concerning valuation relative to its industry. Additionally, the company's recent stock performance shows a stark contrast to the S&P 500, with a 1-week return of -24.62% compared to the index's 1.05%, further reinforcing the notion that Equillium is currently overvalued....

View All News